Interaction of tRNA-derivatives and oligonucleotide primers with AZT-resistant mutants of HIV-1 reverse transcriptase. 1998

O D Zakharova, and O A Suturina, and O A Timofeeva, and S O Gudima, and V I Yamkovoi, and S N Kochetkov, and M Fournier, and L Tarrago-Litvak, and S Litvak, and G A Nevinsky
Novosibirsk Institute of Bioorganic Chemistry, Siberian Division of Russian Academy of Science, Russia.

While the molecular basis of HIV-1 AZT resistance has been widely studied, a biochemical explanation of this process is not well known. No significant changes in the binding affinity of reverse transcriptase (RT) mutants for AZT-triphosphate has been found. Here we analyzed the interaction of wild type and AZT-resistant mutant forms of HIV-1 RT with different primers. Site-directed mutagenesis was used to introduce point mutations on the retroviral enzyme. Primers were either synthetic oligonucleotides or tRNA(Lys3) derivatives containing d(pT)n or r(pU)n at the 3' end. In all cases, determination of kinetic parameters was done in the presence or absence of compounds known to modify protein conformation, such as dimethyl sulfoxide (DMSO), urea, and Triton X-100. Although we found similar K(m) values for all RTs, there was generally an increase in the affinity when enzymes were tested in the presence of DMSO, urea, and Triton X-100. Then, we analyzed the nucleation and elongation steps of the polymerization process. The efficiency of formation of the first base pair was determined by measuring K(m1), the affinity between RT and the 3' terminal nucleotide of the primer. An important difference was found: in the presence of DMSO, urea, and Triton X-100, the K(m1) values for mutated enzymes were higher than those of wild type RTs. Thus, the presence of compounds able to change protein conformation led to a marked destabilization of the interaction of mutated RTs with the 3' terminal nucleotide of the primer. From these results, it can be hypothesized that resistance to AZT is not due to the direct influence of mutations on RT, but rather to conformational changes of the mutated RT in complex with the template-primer altering the ability of the enzyme to select or reject an incoming dNTP.

UI MeSH Term Description Entries
D007700 Kinetics The rate dynamics in chemical or physical systems.
D011994 Recombinant Proteins Proteins prepared by recombinant DNA technology. Biosynthetic Protein,Biosynthetic Proteins,DNA Recombinant Proteins,Recombinant Protein,Proteins, Biosynthetic,Proteins, Recombinant DNA,DNA Proteins, Recombinant,Protein, Biosynthetic,Protein, Recombinant,Proteins, DNA Recombinant,Proteins, Recombinant,Recombinant DNA Proteins,Recombinant Proteins, DNA
D004352 Drug Resistance, Microbial The ability of microorganisms, especially bacteria, to resist or to become tolerant to chemotherapeutic agents, antimicrobial agents, or antibiotics. This resistance may be acquired through gene mutation or foreign DNA in transmissible plasmids (R FACTORS). Antibiotic Resistance,Antibiotic Resistance, Microbial,Antimicrobial Resistance, Drug,Antimicrobial Drug Resistance,Antimicrobial Drug Resistances,Antimicrobial Resistances, Drug,Drug Antimicrobial Resistance,Drug Antimicrobial Resistances,Drug Resistances, Microbial,Resistance, Antibiotic,Resistance, Drug Antimicrobial,Resistances, Drug Antimicrobial
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D012357 RNA, Transfer, Lys A transfer RNA which is specific for carrying lysine to sites on the ribosomes in preparation for protein synthesis. Lysine-Specific tRNA,Transfer RNA, Lys,tRNALys,tRNA(Lys),Lys Transfer RNA,Lysine Specific tRNA,RNA, Lys Transfer,tRNA, Lysine-Specific
D013379 Substrate Specificity A characteristic feature of enzyme activity in relation to the kind of substrate on which the enzyme or catalytic molecule reacts. Specificities, Substrate,Specificity, Substrate,Substrate Specificities
D015215 Zidovudine A dideoxynucleoside compound in which the 3'-hydroxy group on the sugar moiety has been replaced by an azido group. This modification prevents the formation of phosphodiester linkages which are needed for the completion of nucleic acid chains. The compound is a potent inhibitor of HIV replication, acting as a chain-terminator of viral DNA during reverse transcription. It improves immunologic function, partially reverses the HIV-induced neurological dysfunction, and improves certain other clinical abnormalities associated with AIDS. Its principal toxic effect is dose-dependent suppression of bone marrow, resulting in anemia and leukopenia. AZT (Antiviral),Azidothymidine,3'-Azido-2',3'-Dideoxythymidine,3'-Azido-3'-deoxythymidine,AZT Antiviral,AZT, Antiviral,BW A509U,BWA-509U,Retrovir,3' Azido 2',3' Dideoxythymidine,3' Azido 3' deoxythymidine,Antiviral AZT,BWA 509U,BWA509U
D015497 HIV-1 The type species of LENTIVIRUS and the etiologic agent of AIDS. It is characterized by its cytopathic effect and affinity for the T4-lymphocyte. Human immunodeficiency virus 1,HIV-I,Human Immunodeficiency Virus Type 1,Immunodeficiency Virus Type 1, Human
D016297 Mutagenesis, Site-Directed Genetically engineered MUTAGENESIS at a specific site in the DNA molecule that introduces a base substitution, or an insertion or deletion. Mutagenesis, Oligonucleotide-Directed,Mutagenesis, Site-Specific,Oligonucleotide-Directed Mutagenesis,Site-Directed Mutagenesis,Site-Specific Mutagenesis,Mutageneses, Oligonucleotide-Directed,Mutageneses, Site-Directed,Mutageneses, Site-Specific,Mutagenesis, Oligonucleotide Directed,Mutagenesis, Site Directed,Mutagenesis, Site Specific,Oligonucleotide Directed Mutagenesis,Oligonucleotide-Directed Mutageneses,Site Directed Mutagenesis,Site Specific Mutagenesis,Site-Directed Mutageneses,Site-Specific Mutageneses
D054303 HIV Reverse Transcriptase A reverse transcriptase encoded by the POL GENE of HIV. It is a heterodimer of 66 kDa and 51 kDa subunits that are derived from a common precursor protein. The heterodimer also includes an RNAse H activity (RIBONUCLEASE H, HUMAN IMMUNODEFICIENCY VIRUS) that plays an essential role the viral replication process. Reverse Transcriptase, HIV,Reverse Transcriptase, Human Immunodeficiency Virus,Transcriptase, HIV Reverse

Related Publications

O D Zakharova, and O A Suturina, and O A Timofeeva, and S O Gudima, and V I Yamkovoi, and S N Kochetkov, and M Fournier, and L Tarrago-Litvak, and S Litvak, and G A Nevinsky
November 1996, Journal of molecular biology,
O D Zakharova, and O A Suturina, and O A Timofeeva, and S O Gudima, and V I Yamkovoi, and S N Kochetkov, and M Fournier, and L Tarrago-Litvak, and S Litvak, and G A Nevinsky
February 2004, Biochemistry. Biokhimiia,
O D Zakharova, and O A Suturina, and O A Timofeeva, and S O Gudima, and V I Yamkovoi, and S N Kochetkov, and M Fournier, and L Tarrago-Litvak, and S Litvak, and G A Nevinsky
July 1993, FEBS letters,
O D Zakharova, and O A Suturina, and O A Timofeeva, and S O Gudima, and V I Yamkovoi, and S N Kochetkov, and M Fournier, and L Tarrago-Litvak, and S Litvak, and G A Nevinsky
October 1993, Kansenshogaku zasshi. The Journal of the Japanese Association for Infectious Diseases,
O D Zakharova, and O A Suturina, and O A Timofeeva, and S O Gudima, and V I Yamkovoi, and S N Kochetkov, and M Fournier, and L Tarrago-Litvak, and S Litvak, and G A Nevinsky
September 2020, Antimicrobial agents and chemotherapy,
O D Zakharova, and O A Suturina, and O A Timofeeva, and S O Gudima, and V I Yamkovoi, and S N Kochetkov, and M Fournier, and L Tarrago-Litvak, and S Litvak, and G A Nevinsky
December 2023, Protein science : a publication of the Protein Society,
O D Zakharova, and O A Suturina, and O A Timofeeva, and S O Gudima, and V I Yamkovoi, and S N Kochetkov, and M Fournier, and L Tarrago-Litvak, and S Litvak, and G A Nevinsky
April 2006, SAR and QSAR in environmental research,
O D Zakharova, and O A Suturina, and O A Timofeeva, and S O Gudima, and V I Yamkovoi, and S N Kochetkov, and M Fournier, and L Tarrago-Litvak, and S Litvak, and G A Nevinsky
March 2000, The Journal of biological chemistry,
O D Zakharova, and O A Suturina, and O A Timofeeva, and S O Gudima, and V I Yamkovoi, and S N Kochetkov, and M Fournier, and L Tarrago-Litvak, and S Litvak, and G A Nevinsky
June 1992, Biochemical pharmacology,
O D Zakharova, and O A Suturina, and O A Timofeeva, and S O Gudima, and V I Yamkovoi, and S N Kochetkov, and M Fournier, and L Tarrago-Litvak, and S Litvak, and G A Nevinsky
January 2022, Frontiers in virology (Lausanne, Switzerland),
Copied contents to your clipboard!